New precompetitive paradigms: Focus on cardiac safety
To access this article, please choose from the options below
PII: S0002-8703(09)00155-0
doi:10.1016/j.ahj.2009.02.021
© 2009 Mosby, Inc. All rights reserved.
Refers to article:
- Assessing proarrhythmic potential of drugs when optimal studies are infeasible
